Starting July 1, 2019, HMSA will be making Basaglar the preferred long-acting insulin product on the HMSA QUEST Formulary. This is part of our effort to manage the rising cost of prescription drugs while making sure that our members continue to have access to the medications they need.
To help with the conversions, patients using non-preferred long-acting insulin will have until Sept. 30, 2019, to switch to a preferred product. We encourage you to help your patients switch as soon as possible. If your patients decide to stay on the non-preferred insulin, they may have to pay the full cost of the drug.
If you believe your patient should continue taking the current medication, you can request an exception through prior authorization. These requests can be submitted starting July 1, 2019.
Medical Necessity Prior Authorization and Exception Requests
| Call | QUEST Integration: 1-855-220-5732 |
|---|---|
| Fax | QUEST Integration: 1-855-762-5206 toll-free |
| Hours of Operation | 7:45 a.m. to 5 p.m. Hawaii time, Monday through Friday |
| Electronic PA | https://www.covermymeds.com/main/prior-authorization-forms/caremark/ |
|
HMSA Prior Authorization Department P.O. Box 30980 Honolulu, HI 96820-9930 |
For more information, call HMSA’s pharmacy benefits manager at 1-855-479-3656.
Updated formularies are available at HMSA’s QUEST Integration Drug Formulary.
Thank you for your participation with HMSA and your efforts to improve the quality of care for our members. Their health and safety are important and we value your contribution to their well-being.
Revision History
| Date | Nature of Revision |
|---|---|
| 08/03/2026 | Migrated to new platform. |